This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 123 studies, archived under the term: "cholinesterase inhibitors"

Click here to filter this large number of results.

Clinical effects of high oral dose of donepezil for patients with Alzheimer’s disease in Japan
Background: Donepezil 10 mg/day gained approval in Japan in August 2007 for the treatment of cognitive dysfunction in advanced Alzheimer’s disease.; Methods: We evaluated the efficacy and adverse effects of donepezil when the dose was increased to 10 mg/day in 61 Japanese patients with Alzheimer’s disease. Cognitive function was evaluated using the Revised Hasegawa Dementia […]

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
Background: The current study aimed to compare the effects of different cholinesterase inhibitors on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and protein levels, in the cerebrospinal fluid (CSF) of Alzheimer disease (AD) patients.; Methods and Findings: AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. […]

Long-term rivastigmine treatment in a routine clinical setting
Objective: The aim of the study was to observe the effects of long-term rivastigmine treatment in patients with mild to moderate Alzheimer’s disease (AD) in a routine clinical setting.; Methods: This was a prospective, open-label, observational, multicentre, non-randomized study. Outcome measures included the Mini Mental State Examination (MMSE), the Clinician’s Interview-Based Impression of Change (CIBIC) […]

Donepezil delays progression to AD in MCI subjects with depressive symptoms
Objective: To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship.; Methods: The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer’s Disease Cooperative Study drug trial […]

Trospium and cognition in patients with late onset Alzheimer disease
Objectives: Cholinesterase inhibitors for the treatment of Alzheimer’s Disease (AD) and antimuscarinic agents for the treatment of urge urinary incontinence (UUI) may reduce the potential effect of each other in the patients with both diseases. Trospium has a relatively low lipophilicity and low CNS penetration, and galantamine, a cholinesterase inhibitors, has also allosterically modulates nicotinic […]

Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension
The primary objective of the open-label extension was to evaluate the long-term safety and tolerability of a transdermal rivastigmine patch up to 1 year, as a novel approach to treatment in Alzheimer disease. This was a 28-week extension to a 24-week, double-blind, double-dummy, placebo-controlled, and active-controlled study evaluating rivastigmine patches [9.5 mg/24 h (10 cm2) […]

Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial
Background: Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms.; Methods: In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks) or placebo treatment. Primary efficacy variables included change […]

Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study
Visual perception has been shown to be altered in Alzheimer disease (AD) patients, and it is associated with decreased cognitive function. Galantamine is an active cholinergic agent, which has been shown to lead to improved cognition in mild to moderate AD patients. This study examined brain activation in a group of mild AD patients after […]

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study
Acetylcholinesterase inhibitors (AChEIs) have been used to improve cognitive status and disability in patients with mild to moderate Alzheimer’s disease (AD). However, while the efficacy of AChEIs (i.e. how they act in randomized controlled trials) in this setting is widely accepted, their effectiveness (i.e. how they behave in the real world) remains controversial. To compare […]

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
Objective: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects and add-on therapy with memantine, an N-methyl-d-aspartate receptor antagonist, approved for moderate-to-severe AD, may ameliorate such side effects. This was […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us